secwatch.observer — SEC 8-K summary
======================================

Issuer:     Twist Bioscience Corp (TWST)
CIK:        0001581280
Form:       8-K
Filed at:   2024-02-02T23:59:59+00:00
Accession:  0001628280-24-002998
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Twist Bioscience reports record Q1 revenue of $71.5M (+32% YoY); raises FY2024 guidance to $288M-$293M
--------------------------------------------------------------------------------

- Orders increased 19% YoY to $77.5M; NGS revenue grew 61% to $39.4M.
- Net loss of $43.0M ($0.75 per share) vs. $41.8M ($0.74 per share) in prior year.
- Gross margin reached 40.5%, above previous guidance; FY2024 margin guidance raised to 40%-41%.
- Appointed Adam Laponis as CFO; expanded Express Genes service to all prep scales.
- Cash and investments of $311.1M as of Dec 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1581280/000162828024002998/0001628280-24-002998-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1581280/000162828024002998/twist-20240202.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-002998

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer